Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2013; 34(03): 154-158
DOI: 10.4103/0971-5851.123711
COMMENTARY

Chronic myeloid leukemia data from India

Shweta Bansal
Department of Medical Oncology, Asian Institute of Oncology, Mumbai, Maharashtra, India
,
Kumar Prabhash
Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Purvish Parikh
SAARC Federation of Oncology, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

In an effort to collaborate the data of chronic myeloid leukemia (CML) patient from all over India,meeting was conceived by ICON ( Indian Cooperative Oncology Network) in 2010. This article presents the summarized picture of the data presented in the meeting. In the meeting 8115 patients data was presented and 18 centres submitted their manuscripts comprising of 6677 patients. This data represents large series of patients from all over the country treated on day to day clinical practice and presents the actual outcomes of CML patients in India. The compilation of data confirms the younger age at presentation, increased incidence of resistance and poor outcomes in patients with late chronic phase. It also addresses the issues like Glivec versus Generic drug outcomes, safety of Imatinib during pregnancy and mutational analysis among resistant patients. It concludes that survival and quality of life of CML patients in India has improved over the years especially when treated in early chronic phase. The generic drug is a good option where original is unable to reach the patient due to various reasons. Hopefully, this effort will provide a platform to conduct systematic studies in learning the best treatment options among CML patients in Indian settings.

Keywords

Chronic myeloid leukemia - India - Indian cooperative oncology network - mylestone


Publication History

Article published online:
19 July 2021

© 2013. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Lee SJ. Chronic myelogenous leukaemia. Br J Haematol 2000;111:993-1009.
  • 2 Deininger MW, O′Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-47.
  • 3 Leitner AA, Hehlmann R. Modern therapy of chronic myeloid leukemia: an example for paradigma shift in Hemato-oncology.Internist (Berl).2011;52:209-17.
  • 4 O′Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: Sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 2008;112:76.
  • 5 Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51. Available from: http://www.oncologyindia.org/myelstone/. Last accessed on 2013 nov 6.
  • 6 Bhutani M and Kochupillai V. Hematological malignancies in India, in Kumar L (editor): Progress in Hematologic Oncology. Pub. The Advanced Research Foundation New York, New York 2003, p10.
  • 7 Tardieu S, Brun-Strang C, Berthaud P, Michallet M, Guilhot F, Rousselot P, et al. Management of chronic myeloid leukemia in France: a multi-centered cross-sectional study on 538 patients. Pharmacoepidemiol Drug Saf 2005; 14:545-53.
  • 8 Cortes JE, Richard TS, Hagop K. Chronic myelogenous leukemia. In: Padzur R, Coia LR, Hoskins WJ,Wagman LD (eds). Cancer Management: A multidisciplinary approach. 10 th ed. Lawrence: CMPMedica; 2007. p.789.